"Clinical Trials" on a Premature Vascular Aging-on-a-Chip Model

NIH RePORTER · NIH · UG3 · $89,500 · view on reporter.nih.gov ↗

Abstract

Abstract Hutchinson-Gilford progeria syndrome (HGPS) is a genetic disorder that results in premature and accelerated aging, while accumulation of progerin also occurs during physiological aging. Our paratal project seeks to optimize a biomimetic HGPS-on-a-chip system generated with patient-derived fibroblasts (FBs), smooth muscle cells (SMCs), and endothelial cells (ECs) that allow application of relevant cyclic stretch for performing ‘clinical trials’ or informing clinical trial designs for HGPS patients. This supplement further aims at developing in-house protocols for streamlining experimental designs as they relate to data-generation, collection, analyses, storage, as well as deposition into the MPS-Db, specific to the parental grant and in the most meaningful way to the MPS-Db. We anticipate that we will be able to succeed in formulating these streamlined protocols within the 1-year supplement project period that will allow us to both start depositing any data generated in Y2 of the parental project or beyond as soon as they become available, without having to spending additional dedicated efforts in bridging the laboratory-generated data with the MPS-Db.

Key facts

NIH application ID
10432667
Project number
3UG3TR003274-02S1
Recipient
BRIGHAM AND WOMEN'S HOSPITAL
Principal Investigator
Y. Shrike Zhang
Activity code
UG3
Funding institute
NIH
Fiscal year
2021
Award amount
$89,500
Award type
3
Project period
2021-08-25 → 2022-07-31